VistaGen Therapeutics第三季度每股收益$(0.46)超出预期$(0.51),销售额23.4万美元超出预期18万美元

财报速递
14 Feb
VistaGen Therapeutics(NASDAQ:VTGN)报告季度每股亏损$(0.46),超出分析师一致预期的$(0.51),高出9.8%。与去年同期的每股亏损$(0.22)相比,这是109.09%的下降。公司报告季度销售额为23.4万美元,超出分析师一致预期的18万美元,高出30%。与去年同期的41.14万美元相比,这一数据下降了43.12%。

以上内容来自Benzinga Earnings专栏,原文如下:

VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.51) by 9.8 percent. This is a 109.09 percent decrease over losses of $(0.22) per share from the same period last year. The company reported quarterly sales of $234.00 thousand which beat the analyst consensus estimate of $180.00 thousand by 30.00 percent. This is a 43.12 percent decrease over sales of $411.40 thousand the same period last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10